 |
|
|
| |
Prevalence and Impact of
Baseline Resistance-Associated Variants (RAVs)
on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Gary P. Wang, Jackie Reeves, Norah Terrault, Joseph Lim, Giuseppe Morelli, Alexander Kuo, Josh Levitsky, Kenneth Sherman, Lynn M. Frazier, Ananthakrishnan Ramani, Joy Peter, Lucy Akuskevich, Michael W. Fried, David R. Nelson
University of Florida, North Florida/South Georgia Veterans Health System, Monogram Biosciences, University of California, San Francisco, Yale University School of Medicine, University of California, San Diego, Northwestern University Feinberg School of Medicine, University of Cincinnati, Liver Wellness Center, Mountainview Medical Center, University of North Carolina
|
| |
|
|
|
|
|
